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ABSTRACT 
Leishmaniasis is a disease that affects millions of people and it is an important public 
health problem. The drugs currently used for the treatment of leishmaniasis present undesirable 
side effects and low efficacy. In this study, we evaluated the in vitro activity of Melampodium 
divaricatum (MD-EO) and Casearia sylvestris (CS-EO) essential oils (EO) against promastigote 
and amastigote forms of Leishmania amazonensis. Sesquiterpenes E-caryophyllene (56.0%), 
germacrene D (12.7%) and bicyclogermacrene (9.2%) were identified as the main components 
of MD-EO, whereas E-caryophyllene (22.2%), germacrene D (19.6%) and bicyclogermacrene 
(12.2%) were the main constituents of CS-EO. CS-EO and E-caryophyllene were active 
against promastigote forms of L. amazonensis (IC50 24.2, 29.8 and 49.9 µg/mL, respectively). 
However, MD-EO, CS-EO and E-caryophyllene were more active against amastigote forms, 
with IC50 values of 10.7, 14.0, and 10.7 µg/mL, respectively. E-caryophyllene presented lower 
cytotoxicity against macrophages J774-A1 (CC50 of 62.1 µg/mL) than the EO. The EOs and 
E-caryophyllene should be further studied for the development of new antileishmanial drugs.
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INTRODUCTION
Leishmaniasis is an important public health problem and it is estimated that 
2 million new cases occur each year, with at least 15-20 million infected people 
worldwide1,2. Leishmania is the protozoan parasite responsible for leishmaniasis 
which is manifested in visceral, mucocutaneous or cutaneous forms2,3.
Drugs currently recommended for leishmaniasis treatment include compounds 
such as pentavalent antimonials, amphotericin B, lipid formulations of 
amphotericin B (treatment of visceral leishmaniasis) and miltefosine, which is the 
only orally administered drug. However, there are some limitations regarding their 
toxicity, lack of efficacy, need and cost of hospitalization cost4-6. Other problems 
such as re-emerging infectious diseases and resistance to currently used drugs are 
widely recognized as being of serious and immediate concern. Thus, it is imperative 
to search for new drugs against Leishmania parasites7-9.
Plants and their metabolites are potential sources of new antiprotozoal drugs, 
and can contribute to overcome protozoan parasites drug resistance10-12. Many plant 
essential oils have demonstrated anti-Leishmania activity in vivo and in vitro against 
the promastigote and/or the amastigote forms13-16.
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Asteraceae and Salicaceae species have attracted 
special attention due to their therapeutic properties, 
such as anthelmintic, antiinflammatory, astringent, 
antihemorrhagic, antimicrobial, diuretic, analgesic and 
antispasmodic effects17-19. Many species of these families, 
such as Melampodium divaricatum (Rich. ex Rich.) DC. 
(Asteraceae) and Casearia sylvestris Swartz (Salicaceae) 
are aromatic and their essential oils have a large chemical 
complexity. M. divaricatum, popularly known as ‘falsa-
calêndula’, ‘flor-amarela’ or ‘flor-de-ouro’, occurs in 
Northeastern Brazil and is used in folk medicine as wound 
healing, diaphoretic and diuretic. The essential oil from 
the aerial parts of M. divaricatum showed antimicrobial 
activity against S. aureus and B. subtilis16. C. sylvestris 
occurs in Brazil and other countries of Latin America. In 
Brazil, it is known as ‘guaçatonga’, ‘cafezinho-do-mato or 
‘erva-de-lagarto’ and it is used in traditional medicine as 
antiophidic, antiulcer, anti-pyretic, anti-inflammatory and 
wound healing20. However, the antileishmanial activity 
of M. divaricatum and C. sylvestris essential oils has not 
been previously investigated to date. Thus, in this work, we 
report the in vitro antileishmanial activity of the essential 
oils obtained from the aerial parts of M. divaricatum and 
C. sylvestris leaves collected in Brazil and their main 
component E-caryophyllene.
MATERIAL AND METHODS 
Plant material
The aerial parts of Melampodium divaricatum (Rich. 
ex Rich.) DC. (Asteraceae) and leaves of Casearia 
sylvestris Swartz (Salicaceae) were collected at “Medicinal 
Botanical Garden” of School of Pharmaceutical Sciences 
of Sao Paulo State University (UNESP), Araraquara, Sao 
Paulo State, Brazil (21º48’51.4’’ S and 48º12’5.1’’ W). A 
voucher specimen of M. divaricatum (HRCB 35294) and 
C. sylvestris (AGS 102) were deposited at the Herbarium 
Institute of Biosciences of the UNESP Rio Claro, Sao Paulo 
State, Brazil and Herbarium Maria E. P. Kauffman Fidalgo 
of the Botanical Institute of Sao Paulo, Brazil, respectively.
Essential oil extraction and chemicals
Casearia sylvestris essential oil was obtained by 
hydrodistillation of its leaves (150 g) for 4 h in a Clevenger-
type apparatus according to the procedure described in the 
European Pharmacopoeia21. M. divaricatum essential oil 
was obtained by Moreira et al.16. The EOs were stored in 
amber bottles and kept in the refrigerator at 4 °C until further 
analysis. The yields (w/w) were calculated from the weight 
of the fresh aerial parts and leaves of M. divaricatum (0.4%) 
and leaves of C. sylvestris (0.3%). E-Caryophyllene was 
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).
GC/MS analysis
GC-MS analyses were carried out on a Shimadzu 
QP2010 Plus (Shimadzu Corporation, Kyoto, Japan) system 
equipped with an AOC-20i auto sampler. The column 
consisted of Rtx5MS (Restek Co., Bellefonte, PA, USA) 
fused-silica capillary (length = 30 m, i.d. = 0.25 mm, and 
film thickness = 0.25 µm). The electron ionization mass 
spectrometry (EI-MS) mode at 70 eV was employed. 
Helium (99.99%) at a constant flow of 1.0 mL/min was the 
carrier gas. The injection volume was 0.1 µL (split ratio of 
1:10). The injector and the ion source temperatures were 
set at 240 and 280 °C, respectively. The oven temperature 
program was the same as the one used for GC-FID. The 
mass spectra were registered with a scan interval of 0.5 s in 
the mass range of 40 to 600 Da. Essential oil was solubilized 
in hexane (chromatographic grade; Merck®, Darmstadt, 
Germany) 1:100 (v/v).
GC/FID analysis
The essential oil of C. sylvestris (CS-EO) was analyzed 
by gas chromatography (GC) on a Hewlett-Packard G1530A 
6890 gas chromatograph fitted with FID and a data-handling 
processor. An HP-5 (Hewlett-Packard, Palo Alto, CA, USA) 
fused-silica capillary column (length = 30 m, i.d. = 0.25 mm, 
and film thickness = 0.33 µm) was employed. The column 
temperature was programmed to rise from 60 to 240 °C at 
3 °C/min and then held at 240 °C for 5 min. The carrier gas 
was H2 at a flow rate of 1.0 mL/min. The equipment was set 
to the injection mode; the injection volume was 0.1 µL (split 
ratio of 1:10). The injector and detector temperatures were 
240 and 280 °C, respectively. The relative concentrations of 
the components were obtained by peak area normalization 
(%). The relative areas were the average of triplicate 
GC-FID analyses.
Compound identification
Compounds were identified on the basis of their 
retention indices relative to a homologous series of 
n-alkanes (C8–C20). To this end, an Rtx-5MS capillary 
column was employed under the same operating conditions 
as in the case of GC-FID. The retention index (RI) of each 
constituent was determined as described previously22. 
The chemical structures were computer-matched with the 
Wiley7, NIST08, and FFNSC1.2 spectral libraries of the 
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GC-MS data system; their fragmentation patterns were 
compared with the literature data23.
Antileishmanial activity
Parasites and cell culture
Promastigote forms of L. amazonensis (WHOM/BR/75/
Josefa), which were originally isolated by Cesar Augusto 
Cuba-Cuba (Universidade de Brasilia, Brazil) from a 
human case of diffuse cutaneous leishmaniasis. Parasites 
were cultured at 25 °C in Warren’s medium (brain-heart 
infusion plus haemin and folic acid) supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Gibco 
Invitrogen Corporation, New York, USA) in a tissue flask. 
Macrophages (J774-A1) were maintained in tissue flasks 
with RPMI-1640 (pH 7.2) (Gibco Invitrogen, Grand Island, 
NY, USA), added with sodium bicarbonate and L-glutamine 
(As annex), and supplemented with 10% FBS (Gibco 
Invitrogen, Grand Island, NY, USA) at 37 °C in a 5% CO2 
atmosphere24.
Antiproliferative activity studies on promastigote forms
For experiments, promastigote forms in the logarithmic 
phase (1 x 106 cells/mL) were cultured on a 24-well plate 
in Warren’s medium supplemented with 10% of inactivated 
FBS in the presence or absence of different essential oils 
concentrations (1-100 µg/mL). Amphotericin B was used as 
positive control (0.01-10 µg/mL). After 72 h at 28 °C, cell 
growth was estimated using the colorimetric cell viability 
XTT assay (2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-
2H-tetrazolium-5-carboxanilide) (Sigma Chemical Co., 
St. Louis, MO, USA). All experiments were performed in 
duplicate, and the results expressed as log number cells/mL 
and as the percentage of growth inhibition concentration 
that inhibited cell growth in 50% (IC50) was determined by 
nonlinear regression analysis25.
Activity against intracellular amastigote forms
For the antiproliferative activity on intracellular 
amastigotes, peritoneal macrophages from healthy BALB/c 
mice were harvested and plated (3 x 105 cells/mL) in a 
24-well plate with round coverslips using RPMI medium 
supplemented with 10% FBS to adhere for 2 h at 37 °C 
in 5% CO2. Adhered macrophages were infected with 
promastigotes in the stationary growth phase using a ratio 
1:7 at 34 °C for 4 h. Afterwards, non-interiorized parasites 
were removed and the infected culture was treated with 
different concentrations of essential oils (1 to 20 µg/mL) 
at 34 °C. Amphotericin B was used as a positive control 
(0.1-10 µg/mL). After 48 h, the coverslips were washed, 
fixed with methanol and stained with Giemsa. By counting 
200 cells under a light microscope (Olympus CX 31) the 
percentage of infected cells and number of intracellular 
amastigotes were estimated. The survival index (percentage 
of infected cells x number of amastigotes per cell) was 
calculated and IC50 values were then determined by 
nonlinear regression analysis25.
The activity against intracellular amastigote forms 
was compared with toxicity in macrophages, yielding the 
selectivity index (SI; ratio of the CC50 in J774-A1 and the 
IC50 in protozoa).
Cytotoxicity assay
A suspension of J774-A1 macrophages (5 x 105 cells/mL) 
was seeded in 96-well microplates. The cells were allowed 
to attach for 24 h at 37 °C in a 5% CO2 atmosphere. The 
medium was then replaced by different concentrations 
of essential oil (10-1,000 µg/mL). Amphotericin B was 
also evaluated (0.1-10 µg/mL). Cytotoxicity in J774-A1 
macrophages was evaluated after 48 h using the standard 
MTT colorimetric assay26. The mitochondrial-dependent 
reduction of 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl-
tetrazolium bromide (MTT) to formazan was used to 
assess the possible cytotoxic effects of the test compounds 
on murine peritoneal macrophages26. The cytotoxic 
concentration that reduced cell viability by 50% (CC50) was 
estimated by nonlinear regression analysis.
Statistical analysis
One-way ANOVA and the Tukey’s test were performed 
with GraphPad Prism 4 (GraphPad Software, San Diego, 
California, USA). Values of p < 0.05 were considered 
significant.
RESULTS AND DISCUSSION
Essential oil composition 
The essential oils presented as main components 
sesquiterpene hydrocarbons (84.3% for MD-EO and 78.4% 
for CS-EO). E-caryophyllene (56.0%), germacrene D 
(12.7%), bicyclogermacrene (9.2%) and caryophyllene oxide 
(3.0%) were major components of MD-EO employed in 
this study, as previously reported16. The major components 
of CS-EO were E-caryophyllene (22.2%), germacrene D 
(19.6%), bicyclogermacrene (12.2%) and δ-cadinene (6.6%) 
(Figure 1 and Table 1). The sesquiterpenes α-zingiberene, 
E-caryophyllene, germacrene D and bicyclogermacrene 
have been previously reported as the main components in 
the essential oil of C. sylvestris collected in Brazil11,27,28. 
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Table 1 - Composition of the essential oil of C. sylvestris leaves.
Compound name and class*) RT [min]a) RI
exp
b) RIlitc) Content [%]d)
δ-elemene 22.56 1332 1337 1.5
α-cubebene 23.00 1342 1345 2.4
α-longipinene 23.49 1354 1351 3.6
cyclosativene 24.22 1371 1371 0.3
isoledene 24.50 1378 1377 9.0
α-copaene 24.67 1382 1385 0.5
β-cubebene 25.00 1389 1389 0.2
cyperene 25.32 1397 1398 1.8
α-gurjunene 26.06 1415 1412 1.4
E-caryophyllene 26.58 1428 1428 22.2
α-trans-bergamotene 26.86 1436 1436 1.8
Z-β-farnesene 27.10 1442 1442 4.3
α-himachalene 27.29 1447 1447 0.5
α-guaiene 27.43 1450 1447 0.2
β-santalene 27.89 1462 1462 2.7
alloaromadendrene 28.18 1469 1465 0.3
γ-selinene 28.66 1481 1484 0.2
γ-muurolene 28.78 1484 1478 0.4
germacrene D 29.03 1491 1485 19.6
epizonarene 29.23 1496 1497 0.2
bicylogermacrene 29.92 1513 1514 12.2
α-selinene 30.06 1517 1517 1.3
hedycaryol 30.37 1525 1530 1.7
δ-cadinene 30.75 1534 1535 6.6
trans-γ-bisabolene 31.01 1541 1541 0.2
E-α-bisabolene 31.20 1546 1547 0.3
α-colocarene 31.44 1552 1548 0.4
trans-nerolidol 31.85 1562 1564 0.9
caryophyllene alcohol 32.11 1569 1568 0.2
longipinanol 32.41 1576 1575 1.0





aRT: Retention time determined on the Rtx- 5MS capillary column. bRI
exp: Retention index determined relative to n-alkanes (C8–C20) 
on the Rtx-5MS column. cRIlit: Retention index. dCalculated from the peak area relative to the total peak area. Identification: RI, 
comparison of the retention index with the literature29,30; MS, comparison of the mass spectrum with the literature.
Figure 1 - Chemical structures of the major compounds of 
M. divaricatum and C. sylvestris essential oils: 1) E-caryophyllene; 
2) germacrene D; 3) bicyclogermacrene; 4) δ-cadinene.
Antileishmanial activity
The in vitro antileishmanial activity of the MD-EO, 
CS-EO and E-caryophyllene are summarized in Table 2. 
The essential oils and E-caryophyllene were able to inhibit 
promastigote and amastigote growth. The 50% inhibitory 
concentration (IC50) of 24.2, 29.8 and 49.9 µg/mL against 
promastigote forms of L. amazonensis were obtained 
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for MD-EO, CS-EO and E-caryophyllene, respectively. 
Furthermore, MD-EO, CS-EO and E-caryophyllene 
were more active against the amastigote forms than the 
promastigote ones, displaying IC50 values of the 10.7, 14.0 
and 10.7 µg/mL, respectively. Amphotericin B had an IC50 
of 0.06 µg/mL and 0.42 µg/mL against L. amazonensis 
promastigote and amastigote forms, respectively, after 
72h of treatment. These are promising results, given that 
the essential oils and E-caryophyllene proved to be more 
active against amastigote forms, the proliferative form found 
inside mammalian host cells.
Several authors showed the leishmanial effect of the 
essential oils29,30-32 and different biological properties have 
been attributed to a group of sesquiterpenes present in 
these oils33,34.
E-caryophyllene (a sesquiterpene hydrocarbon) was 
the main chemical constituent of the essential oils of 
M. divaricatum and C. sylvestris. According to Santos et al.15, 
essential oils rich in sesquiterpenes, mainly E-caryophyllene, 
showed variable levels of activity against promastigote forms 
of Leishmania with IC50 values in the range between 5 and 
22 µg/mL. Thus, our essential oils showed an antiparasitic 
potency similar to those described in the literature.
The antileishmanial activity of MD-EO and CS-EO 
may be associated with the presence of E-caryophyllene, 
as previously suggested in the literature for other essential 
oils in which E-caryophyllene was one of the main 
components15,29,34,35. E-caryophyllene could also interact 
with other minor components of MD-EO and CS-EO in a 
synergistic way. 
Sesquiterpenes are considered potent skin permeation 
enhancers, and those with leishmanicidal activity would be 
very promising candidates for integration in nanocarriers 
to treat cutaneous leishmaniasis. A mechanism of action 
based on the Leishmania plasma membrane disrupture 
is consistent with the reported broad spectrum of 
sesquiterpene activity against protozoa. It has been shown 
that the lipophilic components of essential oils may affect 
layers of polysaccharides, fatty acids, and phospholipids in 
plasma membranes of Leishmania spp. promastigotes. This 
then leads to cell lysis and release of macromolecules36. In 
the cytoplasm, these compounds can disrupt the specific 
metabolic pathways of lipids and proteins or stimulate the 
depolarization of mitochondrial membranes, which can lead 
to cell necrosis or apoptosis37,38. 
The cytotoxicity of MD-EO, CS-EO and E-caryophyllene 
to macrophages J774-A1 was also evaluated (Table 2). The 
cytotoxicity evaluation of natural products is very important 
for the development of new antiprotozoal agents39. 
Our results revealed that the cytotoxicity of MD-EO 
(CC50 < 10 µg/mL) was higher when compared with CS-EO 
(CC50 = 40.8 µg/mL). However, E-caryophyllene presented 
lower cytotoxicity to macrophages J774-A1 with CC50 value 
equal to 62.1 µg/mL.
The cytotoxicity and the antileishmanial activity were 
compared by using the selectivity index (SI) ratio (CC50 
for J774-A1 cells/IC50 on intracellular amastigotes). Values 
greater than 1 are considered more selective for activity 
against parasites, and a value less than 1 is considered more 
selective for activity against cells. The SI ratio obtained for 
the CS-EO and E-caryophyllene was 2.9 and 5.8, in other 
words they are considered more selective to intracellular 
amastigotes than to mammalian host cells.
CONCLUSIONS
The essential oils of M. divaricatum and C. sylvestris 
displayed antileishmanial activity against both, promastigote 
and amastigote forms of Leishmania amazonensis. Their 
main component E-caryophyllene was more active against 
amastigote forms of L. amazonensis and showed lower 
toxicity, demonstrating a potential as a drug candidate 
against Leishmania. 
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M. divaricatum 24.2 ± 2.1 10.7 ± 2.6 ND <10
C. sylvestris 29.8 ± 1.1 14.0 ± 5.9 2.9 40.8 ± 4.5
E-caryophyllene 49.9 ± 2.6 10.7 ± 0.6 5.8 62.1 ± 1.5
Amphotericin B 0.06 ± 0.0 0.42 ± 0.08 8.8 3.7 ± 0.3
Each value represents the mean ± S.E.M. for three experiments performed in duplicate. IC50: inhibitory concentration for 50%; CC50: 
cytotoxic concentration for 50%; SI: selective index (CC50 macrophages/IC50 against amastigotes). 
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